title: Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
abstract: To evaluate the efficacy of first-line palliative chemotherapy, regarding the presence of signet ring cells (SRC).
  
  
  
  Retrospective analysis of consecutive patients with locally advanced or metastatic gastric or oesogastric junction adenocarcinoma who received first-line chemotherapy. Response to chemotherapy, progression-free survival (PFS) and overall survival (OS) were compared between SRC and non-SRC (NSRC) groups.
  
  
  
  Two hundred and three patients were treated, with 57 (28%) having SRC adenocarcinoma. Objective response rate was significantly lower in SRC patients (5.3% vs. 28.1%, p=0.0004). PFS was not significantly different between SRC and NSRC patients (median=3.8 vs. 4.9 months, p=0.07). OS was significantly shorter in SRC patients (median=5.6 vs. 9.4 months, p<0.008). In multivariate analysis SRC was not an independent prognostic factor for OS (hazard ratio (HR)=1.28, p=0.15).
  
  
  
  Patients with advanced SRC adenocarcinomas seemed to benefit less from chemotherapy, whereas the presence of SRC was not an independent survival prognostic factor.
authors: Department of Medical Oncology, University Hospital, Lille, France.
authors: Nathalie
authors: N
authors: Lemoine
authors: Department of Digestive Oncology, Oscar Lambret Centre, Lille, France.
authors: Antoine
authors: A
authors: Adenis
authors: Department of Digestive Oncology, University Hospital, Reims, France.
authors: Olivier
authors: O
authors: Bouche
authors: Department of Biostatistics, EA2694, University Lille Nord de France, University Hospital, Lille, France.
authors: Alain
authors: A
authors: Duhamel
authors: Department of Digestive Oncology, University Hospital, Reims, France.
authors: Alexandra
authors: A
authors: Heurgue
authors: Department of Pathology, University Lille Nord de France, University Hospital, Lille, France.
authors: Emmanuelle
authors: E
authors: Leteurtre
authors: Department of Digestive Oncology, Oscar Lambret Centre, Lille, France.
authors: Eric
authors: E
authors: Amela
authors: Department of Biostatistics, EA2694, University Lille Nord de France, University Hospital, Lille, France.
authors: Julia
authors: J
authors: Salleron
authors: Department of Medical Oncology, University Hospital, Lille, France mohamed.hebbar@chru-lille.fr.
authors: Mohamed
authors: M
authors: Hebbar
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000473:pathology; D004943:Esophagogastric Junction / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents
keywords: Signet ring cells; gastric adenocarcinoma; oesogastric junction adenocarcinoma; prognosis